B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time

Lupus

Volumn 15, Issue 9, 2006, Pages 570-576

  Becker Merok, A ^a   Nikolaisen, C ^a   Nossent, Hans C ^a,b,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c Department of Rheumatology ^*  (Norway)

Author keywords

Autoantibodies; B cell activating factor; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE ACTIVATING FACTOR; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DNA ANTIBODY; PREDNISONE; PROTEIN; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGE FACTORS; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 33750526860     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306071871     Document Type: Article

References (36)

1. Illei GG, Lipsky PE. Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep 2004; 6: 382-390.
2. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005.
3. Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.
4. Schneider P, Mackay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-1756.
5. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192: 953-964.
6. Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 286-297.
7. Stohl W. SLE - systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther 2003; 5: 136-138.
8. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
9. Gross JA, Dillon SR, Mudri S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease, impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
10. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 19996; 190: 1697-1710.
11. Mackay F, Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol 2002; 23: 113-115.
12. Nikolaisen C, Rekvig OP, Nossent HC. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis. Scand J Rheumatol 2005; 34: 269-276.
13. Nossent HC. Systemic lupus erythematosus in the Arctic region of Norway. J Rheumatol 2001; 28: 539-546.
14. Olaussen E, Rekvig OP. Screening tests for antinuclear antibodies (ANA): selective use of central nuclear antigens as a rational basis for screening by ELISA. J Autoimmun 1999; 13: 95-102.
15. Rekvig OP, Andreassen K, Moens U. Antibodies to DNA - towards an understanding of their origin and pathophysiological impact in systemic lupus erythematosus. Scand J Rheumatol 1998; 27: 1-6.
16. Hernando M, Gonzalez C, Sanchez A et al. Clinical evaluation of a new automated anti-dsDNA fluorescent immunoassay. Clin Chem Lab Med 2002; 40: 1056-1060.
17. Lopez-Hoyos M, Cabeza R, Martinez-Taboada VM et al. Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus. Lupus 2005; 14: 505-509.
18. Bertolaccini ML, Hughes GR, Khamashta MA. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Clin Lab 2004; 50: 653-665.
19. Schellekens GA, Visser H, de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-163.
20. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486.
21. Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep 2002; 4: 345-350.
22. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-1319.
23. Pers JO, Daridon C, Devauchelle V et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34-39.
24. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-201.
25. Youinou P, Jamin C, Pers JO, Berthou C, Saraux A, Renaudineau Y. B lymphocytes are required for development and treatment of autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 19-33.
26. Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 2005; 204: 43-54.
27. Rekvig OP, Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis Rheum 2003; 48: 300-312.
28. Novak AJ, Darce JR, Arendt BK et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103: 689-694.
29. Ramanujam M, Wang X, Huang W et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116: 724-734.
30. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3: 424-429.
31. Gottenberg JE, Sellam J, Ittah M et al. No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjogren's syndrome. Arthritis Res Ther 2006; 8: R30.
32. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 2005; 62: 421-428.
33. Mariette X. [Pathophysiology of Sjogren's syndrome]. Ann Med Interne (Paris) 2003; 154: 157-168.
34. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003; 62: 168-171.
35. Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on the common lymphoid progenitor to pro-B cell transition. J Immunol 2006; 176: 1007-1012.
36. Allman D, Miller JP. B cell development and receptor diversity during aging. Curr Opin Immunol 2005; 17: 463-467.